JP2005527615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527615A5 JP2005527615A5 JP2004506859A JP2004506859A JP2005527615A5 JP 2005527615 A5 JP2005527615 A5 JP 2005527615A5 JP 2004506859 A JP2004506859 A JP 2004506859A JP 2004506859 A JP2004506859 A JP 2004506859A JP 2005527615 A5 JP2005527615 A5 JP 2005527615A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cyclodextrin
- biii
- acid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 229920000858 Cyclodextrin Polymers 0.000 claims 14
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- VCCBCXVFGHTDQN-UODBTFMRSA-N BIII-890CL Chemical compound O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 VCCBCXVFGHTDQN-UODBTFMRSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 239000013543 active substance Substances 0.000 claims 8
- 150000001261 hydroxy acids Chemical class 0.000 claims 8
- 208000006011 Stroke Diseases 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 3
- 239000001630 malic acid Substances 0.000 claims 3
- 235000011090 malic acid Nutrition 0.000 claims 3
- 239000011975 tartaric acid Substances 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- -1 HP-γ-CD Chemical compound 0.000 claims 2
- UWKTVIXWZRROOI-VLIWAZBPSA-N chembl2401795 Chemical compound Cl.O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 UWKTVIXWZRROOI-VLIWAZBPSA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 2
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223783A DE10223783A1 (de) | 2002-05-29 | 2002-05-29 | Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers |
| PCT/EP2003/005399 WO2003099336A1 (de) | 2002-05-29 | 2003-05-23 | Formulierung zur parenteralen applikation eines na-kanal-blockers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527615A JP2005527615A (ja) | 2005-09-15 |
| JP2005527615A5 true JP2005527615A5 (https=) | 2006-07-13 |
Family
ID=29432393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506859A Pending JP2005527615A (ja) | 2002-05-29 | 2003-05-23 | ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1511517B1 (https=) |
| JP (1) | JP2005527615A (https=) |
| AR (1) | AR040134A1 (https=) |
| AT (1) | ATE373492T1 (https=) |
| AU (1) | AU2003237664A1 (https=) |
| CA (1) | CA2487150A1 (https=) |
| DE (2) | DE10223783A1 (https=) |
| ES (1) | ES2294295T3 (https=) |
| PE (1) | PE20040066A1 (https=) |
| TW (1) | TW200400029A (https=) |
| UY (1) | UY27823A1 (https=) |
| WO (1) | WO2003099336A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4239877C1 (de) * | 1992-11-27 | 1994-03-17 | Boehringer Ingelheim Int | Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung |
| DE4313408A1 (de) * | 1993-04-23 | 1994-10-27 | Boehringer Mannheim Gmbh | Cyclodextrin-Biocid-Komplex |
| FR2713934B1 (fr) * | 1993-12-22 | 1996-01-12 | Commissariat Energie Atomique | Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives. |
| DE19740110A1 (de) * | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6565880B2 (en) * | 2000-07-24 | 2003-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| DE10223784A1 (de) * | 2002-05-29 | 2003-12-11 | Boehringer Ingelheim Pharma | Neue Formulierung zur parenteralen Applikation von Crobenetine |
-
2002
- 2002-05-29 DE DE10223783A patent/DE10223783A1/de not_active Withdrawn
-
2003
- 2003-05-23 AT AT03735445T patent/ATE373492T1/de not_active IP Right Cessation
- 2003-05-23 AU AU2003237664A patent/AU2003237664A1/en not_active Abandoned
- 2003-05-23 CA CA002487150A patent/CA2487150A1/en not_active Abandoned
- 2003-05-23 JP JP2004506859A patent/JP2005527615A/ja active Pending
- 2003-05-23 ES ES03735445T patent/ES2294295T3/es not_active Expired - Lifetime
- 2003-05-23 WO PCT/EP2003/005399 patent/WO2003099336A1/de not_active Ceased
- 2003-05-23 EP EP03735445A patent/EP1511517B1/de not_active Expired - Lifetime
- 2003-05-23 DE DE50308227T patent/DE50308227D1/de not_active Expired - Fee Related
- 2003-05-27 PE PE2003000511A patent/PE20040066A1/es not_active Application Discontinuation
- 2003-05-27 UY UY27823A patent/UY27823A1/es not_active Application Discontinuation
- 2003-05-28 TW TW092114414A patent/TW200400029A/zh unknown
- 2003-05-28 AR ARP030101863A patent/AR040134A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131596A5 (https=) | ||
| US20050250738A1 (en) | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | |
| US20030113367A1 (en) | Alprazolam inclusion complexes and pharmaceutical compositions thereof | |
| JP5785175B2 (ja) | スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム | |
| JP2008526757A5 (https=) | ||
| JP2006514923A5 (https=) | ||
| CN113181110A (zh) | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 | |
| JP2003063965A (ja) | 注射用シロスタゾール水性製剤 | |
| JP2020535227A5 (https=) | ||
| JP4384402B2 (ja) | デスフルオロピリドンカルボン酸系化合物を含有する水溶液剤およびその粉末化物並びにそれら製造方法 | |
| CN102697711A (zh) | 地氯雷他定口服液体制剂及其制备方法 | |
| HRP20231337T1 (hr) | Vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu | |
| JP2005527615A5 (https=) | ||
| Granero et al. | Promising complexes of acetazolamide for topical ocular administration | |
| JP5623288B2 (ja) | 医薬組成物 | |
| JP2006052172A5 (https=) | ||
| JP2011502169A5 (https=) | ||
| JP2005527615A (ja) | ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤 | |
| JP2006516279A5 (https=) | ||
| US6828311B2 (en) | Formulation for the parenteral application of a sodium channel blocker | |
| JP3568957B2 (ja) | 改善された医薬特性を示すエストラムスチン処方物 | |
| JP4275394B2 (ja) | 注射用シロスタゾール水性製剤 | |
| JP5853430B2 (ja) | 内服液剤 | |
| JP6239282B2 (ja) | 腎不全改善剤 | |
| US8834932B2 (en) | Anticoagulant-conjugated carbon nanocapsule, antithrombotic agent containing thereof |